Somatostatin treatment of congenital chylothorax may induce transient hypothyroidism in newborns.

Abstract

AIM:

To describe a group of neonates with congenital, non-traumatic chylothorax, one of whom developed transient hypothyroidism following treatment with somatostatin.

METHODS:

The charts of seven infants with congenital chylothorax were reviewed in terms of their clinical presentation, the severity of their disease, the complications they presented and the duration of their hospitalization. Their pituitary-thyroid axis function was monitored in particular.

RESULTS:

The seven infants, all preterm (32-34 wk), suffered from congenital chylothorax and hydrops fetalis diagnosed during the prenatal period. Four were treated by intrauterine drainage, and four had congenital malformations. Hospitalization lasted from 32 to 120 d. Three of the infants suffered from thrombocytopenia, three had chronic lung disease, and one suffered from Gram-negative sepsis. The infant treated with somatostatin initially had normal thyroid function, but later developed primary transient hypothyroidism and was treated with L-thyroxine. The thyroid screening tests for the infants who were not treated with somatostatin were all normal.

CONCLUSIONS:

Repeated doses of somatostatin were effective in reducing chylus production. Administering this treatment earlier should be considered in order to minimize known complications. The only potential side effect observed was primary transient hypothyroidism. Therefore, careful monitoring of the pituitary-thyroid axis is advised.

• Authors: Ayala Maayan-Metzger, Joseph Sack, Ram Mazkereth, Amir Vardi, Jacob Kuint
• Journal: Acta paediatrica (Oslo, Norway : 1992) (Acta Paediatr) Vol. 94 Issue 6 Pg. 785-9 (Jun 2005) ISSN: 0803-5253 [Print] Norway
• PMID: 16188789 (Publication Type: Journal Article)

Chemical References

• Somatostatin

Topics

• Chylothorax (congenital, drug therapy)
• Humans
• Hypothyroidism (chemically induced)
• Infant
• Infant, Newborn
• Somatostatin (adverse effects)